Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

RSV monoclonal antibody, clesrovimab,” which was approved by the FDA yesterday, Leerink Partners LLC analyst Daina Graybosch said. Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Hib vaccination. Centers for Disease Control and Prevention. Polio vaccination. Centers for Disease Control and Prevention. Pneumococcal vaccine recommendations. Centers for Disease Control and ...

Serogroup X is less common and does not yet have a vaccine available. Haemophilus influenzae type b (Hib) bacteria used to be the top ... even from a splenectomy). Merck Manual Consumer Version.

A class-action lawsuit claims Merck overcharged for a less potent mumps vaccine, violating the Sherman Act. The District Court denied Merck's summary judgment, acknowledging ethical issues but ...

The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia.

The Food and Drug Administration on Monday approved Merck’s new pneumococcal vaccine for adults 18 and older. The vaccine, which will be sold under the name Capvaxive, is designed to protect ...